All Posts By

Hannah Burson

Oncology News Central
“What I Tell My Patients:” Making Sense of New Treatment Options in EGFR-positive NSCLC StoriesTreatments

“What I Tell My Patients:” Making Sense of New Treatment Options in EGFR-positive NSCLC

*September 2025* In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, from Vanderbilt University, to talk about the complexities of treating advanced EGFR-positive non-small cell lung cancer. Dr. Lovely shares how she talks with…
Hannah Burson
March 12, 2026
COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC ResearchTreatments

COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC

*September 2025* A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study showed that continuing osimertinib with the addition…
Hannah Burson
March 11, 2026